In this early phase, patients affected by Ph + CML, are treated with tyrosine kinase inhibitors (TKIs) that target BCR-ABL, however, primary or secondary resistance is observed in about 20% of patients22–24. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.